Halofantrine indications and usage

Jump to navigation Jump to search
Halofantrine
HALFAN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Indications and Usage

Halfan tablets are indicated for the treatment of adults who can tolerate oral medication and who have mild to moderate malaria (equal to or less than 100,000 parasites/mm3) caused by Plasmodium falciparum or Plasmodium vivax.

NOTE: Patients with acute P. vivax malaria treated with Halfan are at risk of relapse because halofantrine does not eliminate the exoerythrocytic (hepatic phase) parasites. To avoid relapse after initial treatment of the acute P. vivax infection with Halfan, patients should subsequently be treated with an 8-aminoquinoline to eradicate the exoerythrocytic parasites.

NOTE: THE EFFICACY OF HALFAN (HALOFANTRINE HYDROCHLORIDE) IN THE PROPHYLAXIS OF MALARIA HAS NOT BEEN ESTABLISHED.[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20250s7s8lbl.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.